AFC
DYN icon

Ares Financial Consulting’s Dyne Therapeutics DYN Stock Holding History

Ares Financial Consulting’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87K Buy
+84
New +$1.56K ﹤0.01% 901

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Ares Financial Consulting's DYN Position: Q2 2026 in Review

Ares Financial Consulting opened a new position in Dyne Therapeutics (DYN) in Q2 2026: 84 shares worth $1.87K. The stake represents ﹤0.01% of the portfolio and ranks #901 among its holdings.

245 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Ares Financial Consulting held 84 shares of Dyne Therapeutics worth $1.87K as of Q2 2026.
  • Dyne Therapeutics was a new Ares Financial Consulting position in Q2 2026.
  • Dyne Therapeutics made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #901 holding.
  • 245 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.